References
- Louis DN, Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1: 97-117. 10.1146/annurev.pathol.1.110304.100043
- Mesti T, Moltara ME, Boc M, Rebersek M,Ocvirk J, Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol Oncol 2015; 49: 80-5. 10.2478/raon-2014-0021
- Qureshi IA, Mattick JS,Mehler MF, Long non-coding RNAs in nervous system function and disease. Brain Res 2010; 1338: 20-35. 10.1016/j.brain-res.2010.03.110
- Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, Kennett JY, et al., Human cancer long non-coding RNA transcriptomes. PLoS One 2011; 6: e25915. 10.1371/journal.pone.0025915
- Qureshi IA,Mehler MF, Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat Rev Neurosci 2012; 13: 528-41. 10.1038/nrn3234
- Zhang X, Sun S, Pu JK, Tsang AC, Lee D, Man VO, et al., Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis 2012; 48: 1-8. 10.1016/j.nbd.2012.06.004
- Gibb EA, Brown CJ,Lam WL, The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011; 10: 38. 10.1186/1476-4598-10-38
- Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al., Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-7. 10.1038/nature07672
- Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al., Landscape of transcription in human cells. Nature 2012; 489: 101-8. 10.1038/nature11233
- Weichenhan D,Plass C, The evolving epigenome. Hum Mol Genet 2013; 22: R1-6. 10.1093/hmg/ddt348
- Hassler MR,Egger G, Epigenomics of cancer - emerging new concepts. Biochimie 2012; 94: 2219-30. 10.1016/j.biochi.2012.05.007
- Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, et al., Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 2013; 9: e1003368. 10.1371/journal.pgen.1003368
- Tian D, Sun S,Lee JT, The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. Cell 2010; 143: 390-403. 10.1016/j.cell.2010.09.049
- Lee C,Kikyo N, Strategies to identify long noncoding RNAs involved in gene regulation. Cell Biosci 2012; 2: 37. 10.1186/2045-3701-2-37
- Kitagawa M, Kitagawa K, Kotake Y, Niida H,Ohhata T, Cell cycle regulation by long non-coding RNAs. Cell Mol Life Sci 2013; 70: 4785-94. 10.1007/s00018-013-1423-0
- Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, et al., LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. Int J Oncol 2012; 40: 2004-12. 10.3892/ijo.2012.1413
- Mercer TR,Mattick JS, Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 2013; 20: 300-7. 10.1038/nsmb.2480
- Karapetyan AR, Buiting C, Kuiper RA,Coolen MW, Regulatory Roles for Long ncRNA and mRNA. Cancers (Basel) 2013; 5: 462-90. 10.3390/cancers5020462
- Kanduri C, Long noncoding RNAs: Lessons from genomic imprinting. Biochim Biophys Acta 2016; 1859: 102-11. 10.1016/j.bbagrm.2015.05.006
- Fietkau R, Putz F, Lahmer G, Semrau S,Buslei R, Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution. Strahlenther Onkol 2013; 189: 993-5. 10.1007/s00066-013-0459-2
- Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac V, et al., Longterm survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor, in Radiol Oncol 2016; 50: 394-401. 10.1515/raon-2015-0041
- Shi X, Sun M, Liu H, Yao Y,Song Y, Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett 2013; 339: 159-66. 10.1016/j.canlet.2013.06.013
- Bian EB, Li J, Xie YS, Zong G,Zhao B, LncRNAs: New Players in Gliomas, with Special Emphasis on the Interaction of lncRNAs With EZH2. J Cell Physiol 2015; 230: 496-503. 10.1002/jcp.24549
- Alelu-Paz R, Ashour N, Gonzalez-Corpas A,Ropero S, DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology. J Signal Transduct 2012; 2012: 956958. 10.1155/2012/956958
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. 10.1007/s00401-007-0243-4
- Livak KJ,Schmittgen TD, Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8. 10.1006/meth.2001.1262
- Li J, Bian EB, He XJ, Ma CC, Zong G, Wang HL, et al., Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas. Int J Oncol 2016; 48: 723-33. 10.3892/ijo.2015.3285
- Wang P, Ren Z,Sun P, Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem 2012; 113: 1868-74. 10.1002/jcb.24055
- Park JY, Lee JE, Park JB, Yoo H, Lee SH,Kim JH, Roles of Long Non-Coding RNAs on Tumorigenesis and Glioma Development. Brain Tumor Res Treat 2014; 2: 1-6. 10.14791/btrt.2014.2.1.1
- Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, et al., Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett 2015; 359: 75-86. 10.1016/j.canlet.2014.12.051
- He C, Jiang B, Ma J,Li Q, Aberrant NEAT1 expression is associated with clinical outcome in high grade glioma patients. Apmis 2016; 124: 169-74. 10.1111/apm.12480
- Wang Q, Zhang J, Liu Y, Zhang W, Zhou J, Duan R, et al., A novel cell cycleassociated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett 2016; 373: 251-9. 10.1016/j.canlet.2016.01.039
- Ohgaki H,Kleihues P, The definition of primary and secondary glioblastoma. Clin Cancer Res 2013; 19: 764-72. 10.1158/1078-0432.ccr-12-3002
- Wojdacz TK,Dobrovic A, Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007; 35: e41. 10.1093/nar/gkm013
- Switzeny OJ, Christmann M, Renovanz M, Giese A, Sommer C,Kaina B, MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Clin Epigenetics 2016; 8: 49. 10.1186/s13148-016-0204-7
- Hagedorn M, Siegfried G, Hooks KB,Khatib AM, Integration of zebrafish fin regeneration genes with expression data of human tumors in silico uncovers potential novel melanoma markers. Oncotarget 2016; 7: 71567-71579. 10.18632/oncotarget.12257
- Legendre CR, Demeure MJ, Whitsett TG, Gooden GC, Bussey KJ, Jung S, et al., Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer. PLoS One 2016; 11: e0150629. 10.1371/journal.pone.0150629
- Yang Z, Xu S, Jin P, Yang X, Li X, Wan D, et al., MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis. Oncotarget 2016; 7: 37649-37663. 10.18632/oncotarget.8726
- Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, et al., Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res 2009; 69: 7548-56. 10.1158/0008-5472.can-08-4783
- Rohrbach TD, Shah N, Jackson WP, Feeney EV, Scanlon S, Gish R, et al., The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization. PLoS One 2015; 10: e0140870. 10.1371/journal.pone.0140870
- Rohrbach TD, Jarboe JS, Anderson JC, Trummell HQ, Hicks PH, Weaver AN, et al., Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity. Int J Oncol 2015; 46: 1079-88. 10.3892/ijo.2014.2799
- Hanada S, Kakehashi A, Nishiyama N, Wei M, Yamano S, Chung K, et al., Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma. Cancer Biomark 2013; 13: 289-98. 10.3233/cbm-130354
- Punzi G, Ursini G, Shin JH, Kleinman JE, Hyde TM,Weinberger DR, Increased expression of MARCKS in post-mortem brain of violent suicide completers is related to transcription of a long, noncoding, antisense RNA. Mol Psychiatry 2014; 19: 1057-9. 10.1038/mp.2014.41
- Ropero S,Esteller M, The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19-25. 10.1016/j.molonc.2007.01.001
- Li Z,Zhu WG, Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci 2014; 10: 757-70. 10.7150/ijbs.9067
- Conte M, Dell’Aversana C, Benedetti R, Petraglia F, Carissimo A, Petrizzi VB, et al., HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. Oncotarget 2015; 6: 886-901. 10.18632/oncotarget.2816
- Alzoubi S, Brody L, Rahman S, Mahul-Mellier AL, Mercado N, Ito K, et al., Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. Oncotarget 2016; 7: 44505-44521. 10.18632/oncotarget.9887
- Qu X, Yu H, Jia B, Yu X, Cui Q, Liu Z, et al., Association of downregulated HDAC 2 with the impaired mitochondrial function and cytokine secretion in the monocytes/macrophages from gestational diabetes mellitus patients. Cell Biol Int 2016; 40: 642-51. 10.1002/cbin.10598
- Stojanovic N, Hassan Z, Wirth M, Wenzel P, Beyer M, Schafer C, et al., HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene 2016. 10.1038/onc.2016.344
- Campos B, Bermejo JL, Han L, Felsberg J, Ahmadi R, Grabe N, et al., Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 2011; 102: 387-92. 10.1111/j.1349-7006.2010.01792.x